- Home
- VTYX vs EPRX Comparison
VTYX vs EPRX Comparison
Compare VTYX & EPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VTYX
- EPRX
- Stock Information
- Founded
- VTYX 2018
- EPRX 2011
- Country
- VTYX United States
- EPRX Canada
- Employees
- VTYX N/A
- EPRX N/A
- Industry
- VTYX Medicinal Chemicals and Botanical Products
- EPRX
- Sector
- VTYX Health Care
- EPRX
- Exchange
- VTYX Nasdaq
- EPRX NYSE
- Market Cap
- VTYX 154.9M
- EPRX 111.1M
- IPO Year
- VTYX 2021
- EPRX N/A
- Fundamental
- Price
- VTYX $1.17
- EPRX $3.83
- Analyst Decision
- VTYX Buy
- EPRX Strong Buy
- Analyst Count
- VTYX 4
- EPRX 1
- Target Price
- VTYX $11.33
- EPRX $9.00
- AVG Volume (30 Days)
- VTYX 965.2K
- EPRX 15.4K
- Earning Date
- VTYX 05-16-2025
- EPRX 05-06-2025
- Dividend Yield
- VTYX N/A
- EPRX N/A
- EPS Growth
- VTYX N/A
- EPRX N/A
- EPS
- VTYX N/A
- EPRX N/A
- Revenue
- VTYX N/A
- EPRX N/A
- Revenue This Year
- VTYX N/A
- EPRX N/A
- Revenue Next Year
- VTYX N/A
- EPRX N/A
- P/E Ratio
- VTYX N/A
- EPRX N/A
- Revenue Growth
- VTYX N/A
- EPRX N/A
- 52 Week Low
- VTYX $0.78
- EPRX $2.20
- 52 Week High
- VTYX $5.66
- EPRX $4.48
- Technical
- Relative Strength Index (RSI)
- VTYX 46.01
- EPRX N/A
- Support Level
- VTYX $1.05
- EPRX N/A
- Resistance Level
- VTYX $1.48
- EPRX N/A
- Average True Range (ATR)
- VTYX 0.11
- EPRX 0.00
- MACD
- VTYX 0.01
- EPRX 0.00
- Stochastic Oscillator
- VTYX 27.91
- EPRX 0.00
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
About EPRX EUPRAXIA PHARMACEUTICALS INC
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.